Mycophenolate mofetil and its mechanisms of action

Immunopharmacology

Volumn 47, Issue 2-3, 2000, Pages 85-118

  Allison, Anthony C ^a,b   Eugui, Elsie M ^a,b  

^a 1060 E Meadow Circle   (United States)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

Adhesion molecules; CellCept ; Chronic rejection; Immunosuppression; Inosine monophosphate dehydrogenase; Mycophenolate mofetil; Mycophenolic acid; Nitric oxide

Indexed keywords

CELL ADHESION MOLECULE; GUANOSINE; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ALLOGRAFT; DRUG MECHANISM; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; REVIEW;

EID: 0034045586     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(00)00188-0     Document Type: Article

References (161)

1. Al-Akash S., Ettenger R., Gales B.et al. Influenza vaccine antibody response in pediatric renal transplant patients treated with newer immunosuppressive agents. J. Am. Soc. Nephrol. 9:1998;663A. (Abstr).
2. Alfieri C., Allison A.C., Kieff E. Effect of mycophenolic acid on Epstein-Barr virus infection of human B-lymphocytes. Antimicro. Agents Chemother. 38:1994;126-129.
3. Allison A.C. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology. 47:2000;63-83.
4. Allison A.C., Almquist S.J., Muller C.D., Eugui E.M. In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS-61443. Transplant. Proc. 23(Suppl. 2):1991;10-14.
5. Allison A.C., Eugui E.M. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin. Immunopathol. 14:1993;353-380.
6. Allison A.C., Hovi T., Watts R.W.E., Webster A.D.B. Immunological observations on patients with the Lesch-Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation. Lancet. II:1975;1179-1183.
7. Allison A.C., Hovi T., Watts R.W.E., Webster A.D.B. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found. Symp. 48:1977;207-223.
8. Allison A.C., Kowalski W.J., Muller C.J.et al. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant. Proc. 25(Suppl. 2):1993;67-70.
9. Altmann D.M., Hogg N., Trowsdale J., Wilkinson D. Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting function in mouse L cells. Nature. 338:1989;512-514.
10. Ando K., Hiroishi K., Kaneko T.et al. Perforin, Fas/Fas ligand and TNF-α pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J. Immunol. 158:1997;5283-5291.
11. Azuma H., Binder J., Heeman U.et al. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation. 59:1995;460-466.
12. Bagasra D., Michaels F.H., Zheng Y.M.et al. Activation of the inducible nitric oxide synthase in brains of patients with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;12041-12045.
13. Benvenuti C., Bories P.N., Loisance D. Increased serum nitrate concentration in cardiac transplant patients. A marker for acute allograft cellular rejection. Transplantation. 61:1996;745-749.
14. Berman J.D., Webster H.K. In vitro effects of mycophenolic acid and allopurinol against Leishmania tropica in human macrophages. Antimicro. Agents Chemother. 21:1982;887-891.
15. Bird A.G. Cyclosporin A, lymphomata and Epstein-Barr virus. White D.J. Cyclosporin A. 1982;307-315 Elsevier, Amsterdam.
16. Birkeland S.A. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation. 66:1988;1207-1210.
17. Blaheta R.A., Leckel K., Wittig B.et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant. Proc. 31:1999;1250-1252.
18. Böhm M., Beissert S., Schwartz T.et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet. 1997;349-351.
19. Borel J.F., Feurer C., Gubler H.V.et al. Biological effects of cyclosporein A: a new anti-lymphocyte agent. Agents Actions. 6:1976;468-475.
20. Briggs W.A., Choi M.J., Scheel P.J. Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am. J. Kidney Dis. 31:1998;213-217.
21. 51Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and drugs. J. Immunol. 14:1988;181-196.
22. Byars N.E., Nakano G.M., Kang R., Allison A.C. Oral administration of mycophenolic acid selectively depletes GTP in lymph node cells of immunized rats. 9th Internat. Congr. Immunology, Abstract 855. 1995.
23. Carr S.F., Papp E., Wu J.C., Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J. Biol. Chem. 268:1993;27286-272902.
24. Chanaud N.P. III, Vistica B.P., Eugui E.et al. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp. Eye Res. 61:1995;429-434.
25. Chang C.-C.J., Aversa G., Punnonen J., Yssel H., de Vries J. Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4 or IL-3-induced human IgG4 and IgE production in vitro. Ann. N. Y. Acad. Sci. 696:1993;108-122.
26. Cohn R.G., Mirkovich A., Caulfield J., Eugui E.M. Apoptosis of human activated peripheral T-cells and T-lymphocytic and promonocytic cell lines induced by mycophenolic acid, the active metabolite of CellCept. The Sixth Basic Sciences Symposium of the Transplantation Society, Monterey, CA. 1999;173.
27. Cohn R.G., Mirkovich A., Dunlap B.et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation. 68:1996;411-418.
28. Corna D., Morigi M., Facchinettiet al. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int. 51:1997;1583-1589.
29. Dissanayake I.R., Goodman G.R., Bowman A.R.et al. Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation. 65:1998;275-278.
30. Dodge I.L., Li X.C., Ström T.B. Rapamycin induces TGF-β production in lymphocytes. Transplantation. 67:1999;S50.
31. Enk A.H., Knop J. Treatment of relapsing idiopathic nodular panniculitis (Pfeiffer-Weber-Christian disease) with mycophenolate mofetil. J. Am. Acad. Dermatol. 39:1998;508-509.
32. Enk A.H., Knop J. Mycophenolate mofetil is effective in the treatment of pemphigus vulgaris. Arch. Dermatol. 135:1999;54-56.
33. Eugui E.M., Almquist S., Muller C.D., Allison A.C. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand. J. Immunol. 33:1991;161-173.
34. Eugui E.M., Mirkovich A., Allison A.C. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand. J. Immunol. 33:1991;175-183.
35. Eugui E.M., Nakano G.M., Byars N.E. Effect of mycophenolic acid on antibody titers and isotypes in mice vaccinated with influenza virus hemagglutinin. 9th Internat. Congr. Immunology, Abstracts 5073. 1995.
36. Fairbanks L.D., Bofill M., Ruckemann K., Simmonds H.A. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J. Biol. Chem. 270:1995;29682-29689.
37. Franklin T.J., Cook J.M. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem. J. 113:1969;515-524.
38. Fraser-Smith E.B., Rosette J.D., Schatzman R.C. Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis model. J. Pharmacol. Exp. Ther. 275:1995;1204-1208.
39. Fujihara C.K., Malheiros D.M., Zatz R., Noronha I.D. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int. 45:1998;1510-1519.
40. Garcia R.C., Leoni P., Allison A.C. Control of phosphoribosyl pyrophosphate synthesis in human lymphocytes. Biochem. Biophys. Res. Commun. 77:1977;1067-1073.
41. Geilen C.C., Tebbe B., Garcia-Bartels C., Krengel S., Orfanos C.E. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br. J. Dermatol. 138:1998;1101-1102.
42. Giblett E.R., Anderson J.E., Cohen F., Meuwissen H.J. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. II:1972;1067-1069.
43. Glinklich D., Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am. J. Kidney Dis. 32:1998;318-322.
44. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin. Exp. Rheumatol. 11:1993;S117-119. (Suppl.).
45. Goto M., Yamaguchi Y., Ichiguchi O.et al. Phenotype and localization of macrophages expressing inducible nitric oxide synthase in rat hepatic allograft rejection. Transplantation. 64:1997;303-310.
46. Grailer A., Nichols J., Hullett D., Sollinger H.W., Burlingham W.J. Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and FK506. Transplant. Proc. 23:1991;314-315.
47. Green C.J., Allison A.C. Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin A treatment. Lancet. ii:1978;1182-1184.
48. Green C.J., Allison A.C., Precious S. Induction of specific tolerance in rabbits by kidney allografting and short period of cyclosporin A therapy. Lancet. ii:1979;123-125.
49. Gregory C.R., Huang X.et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 59:1995;655-661.
50. Gregory C.D., Murray R.J., Edwards C.F., Rickinson A.D. Down regulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J. Exp. Med. 167:1988;1811-1824.
51. Gregory C.R., Pratt R.E., Huie P.et al. Effects of treatment with cyclosporine, FK-506, rapamycin, mycophenolic acid, or dexoyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc. 25:1993;770-771.
52. Grundmann-Kollman M., Korting H.C.et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J. Am. Acad. Dermatol. 40:1999;957-960.
53. Hao L., Calcinaro F., Gill R.G.et al. Facilitation of tolerance induction in adult mice by RS-61443. Transplantation. 53:1992;590-595.
54. Hao L.M., Chan S.M., Lafferty K.J. Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann. N. Y. Acad. Sci. 696:1993;328-332.
55. Hao L., Lafferty K.J., Allison A.C., Eugui E.M. RS-61443 allows islet allografting and specific tolerance induction in adult mice. Transplant Proc. 22:1990;876-879.
56. Haufs M.G., Beissert S., Grabbe S., Schutte B., Luger T.A. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br. J. Dermatol. 138:1998;179-181.
57. Hauser I.A., Bernd Sterzel R. Mycophenolate mofetil: therapeutic applications in kidney transplantation and immune-mediated renal disease. Curr. Opin. Nephrol. Hypertens. 8:1999;1-6.
58. Hauser R.A., Malek A.R., Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology. 51:1998;912-913.
59. Hauser I.A., Johnson D.R., Thévenod F., Goppelt-Strübe M. Effect of mycophenolic acid on TNF alpha-induced expression of cell adhesion molecules in human venous endothelial cells in vitro. Br. J. Pharmacol. 122:1997a;1315-1322.
60. Hauser I.A., Renders L., Merkel C., Goppelt-Struebe M. Mycophenolate mofetil, but not cyclosporin A or FK506, inhibits rat mesangial cell proliferation in vitro. J. Am. Soc. Nephrol. 9:1997b;496A. (Abstr).
61. Häyry P., Isoniemi H., Yilmaz S.et al. Chronic allograft rejection. Immunol. Rev. 134:1993;33-81.
62. Heemann U., Azuma H., Hamar P.et al. Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allografts. Transplant. Immunol. 4:1996;64-67.
63. Heering P., Heise G., Hess A. MMF reduces proteinuria in passive Heymann nephritis. J. Am. Soc. Nephrol. 9:1998;456A-457A. (Abstr).
64. Hohenleutner U., Mohr V.D., Michel S., Landthaler M. Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum. Lancet. 350:1997;1748.
65. Hovi T., Allison A.C., Allsop J. Rapid increase of phosphoribosyl pyrophosphate concentration after mitogenic stimulation of lymphocytes. FEBS Lett. 55:1975;291-293.
66. Hovi T., Allison A.C., Raivio K.O., Vaheri A. Purine metabolism and control of cell proliferation. Ciba Found. Symp. 48:1977;225-248.
67. Huang Q.-Y., Ye W.-L., Zheng F.-L. Effect of mycophenolate mofetil on anti-Thy-1 mesangial proliferative glomerulonephritis. J. Am. Soc. Nephrol. 9:1998;496A.
68. Hupe D.J., Azzolina B.A., Behrens N.D. IMP dehydrogenase from the intracellular parasitic protozoan Eimeria tenella and its inhibition by mycophenolic acid. J. Biol. Chem. 261:1986;8363-8369.
69. Ichimura H., Levy J.A. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology. 211:1995;554-560.
70. Isobe M., Yagita H., Okumura K., Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science. 255:1992;1125-1127.
71. Jackson R.C., Morris H.P., Weber G. Partial purification, properties and regulation of inosine 5′-phosphate dehydrogenase in normal and malignant rat tissues. Biochem. J. 166:1977;1-10.
72. Keown P.A.et al. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 61:1996;1029-1037.
73. Khanna A. TGF-beta provides the rationale for the synergistic immunosuppression with rapamycin (RAPA), cyclosporine (CsA) and tacrolimus (TAC) calcineurin inhibitors sparing immunosuppression protocol. Transplantation. 67:1999;S58.
74. Koglin J., Granville D.J., Glysing-Jensen T.et al. Attenuated acute cardiac rejection in NOS2-/- recipients. Circulation. 99:1999;836-842.
75. Koglin J., Glysing-Jensen T., Mudgett S.S., Russell M.E. NOS2 mediates opposing effects in models of acute and chronic cardiac rejection: insights from NOS2-knockout mice. Am. J. Pathol. 153:1998;1371-1376.
76. Konno Y., Natsumeda Y., Nagai M.et al. Expression of IMP dehydrogenase types I and II in Escherichia coli and distribution in normal human lymphocytes and leukemic cell lines. J. Biol. Chem. 266:1991;506-509.
77. Kornfeld R., Kornfeld S. Structure of glycoproteins and their oligosaccharide units. Lennarz W.J. Biochemistry Glycoproteins and Proteoglycans. 1980;1-137 Plenum, New York.
78. Larkin G., Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthomology. 106:1999;370-374.
79. Laski L.A. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science. 258:1992;964-969.
80. Laurent A.F., Dumont S., Poindron P., Muller C.D. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and some substrates. Exp. Hematol. 24:1996;59-67.
81. Lee W.A., Gu L., Miksztal A.R., Chu N.et al. Bioavailability improvement of mycophenolic acid through amino ester derivitization. Pharm. Res. 7:1990;161-166.
82. Leoni P., Garcia R.C., Allison A.C. Effects of cyclosporin A on human lymphocytes in culture. J. Lab. Clin. Immunol. 1:1978;67-75.
83. Li L.-S., Liu Z.-H., Hong Z., Hu W.-X. Mycophenolate mofetil showed inhibitory effect on VCAM expression during successful treatment of diffuse proliferative lupus nephritis (SLE-DPGN) with vascular lesions. J. Am. Soc. Nephrol. 9:1998;153A.
84. Margolis D., Heredia A., Gaywee J. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J. AIDS. 1999;. (in press).
85. Maurizio S., Bertoni E., Rosati A.et al. Mycophenolate mofetil (MMF) prevents acute rejection and assures high one-year graft survival also in the case of delayed graft function. J. Am. Soc. Nephrol. 9:1998;696A. (Abstr).
86. McMurray R.W., Ellbourne K., Lagoo A.et al. Mycophenolate mofetil suppresses autoimmunity and mortality in the female (NZB×NZW)F1 mouse model of systemic lupus erythematosis. J. Rheumatol. 25:1998;2364-2370.
87. Mirkovich A., Eugui E.M. Prevention of murine graft-versus-host disease (GVHD) by mycophenolate mofetil. 9th Internat. Congr. Immunol. (Abstr). 1995;2523.
88. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43:1991;109-142.
89. Morris R.E., Hoyt E.G., Murphy M.P., Eugui E.M., Allison A.C. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T and B cell purine synthesis. Transplant. Proc. 22:1990;1659-1662.
90. Morris R.E., Wang J., Blum J.R.et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant. Proc. 23(Suppl. 2):1991;19-25.
91. Mueller V., Hamar P., Szabo A.et al. Effect of mycophenolate mofetil on the in vivo infiltration of lymphocytes in the rat remnant kidney. Transplant. Proc. 30:1998;982.
92. Mulkins M.A., Ng M., Lewis R.G. Mycophenolic acid inhibits the degranulation of rat peritoneal mast cells. Cell. Immunol. 141:1992;508-517.
93. Nachman P.H., Dooley M.A., Hogan S.L.et al. Mycophenolate mofetil therapy in patients with cyclophosphamide-(CyP) resistant or relapsing diffuse proliferative lupus nephritis (SLE-DPGN). J. Am. Soc. Nephrol. 9:1997;94A.
94. Nadeau K.C., Azuma H., Tilney N.L. Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil. Transplantation. 62:1996;1363-1366.
95. Nagai M., Natsumeda Y., Weber G. Proliferation-linked regulation of the type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res. 52:1992;258-261.
96. Nagy S.E., Andersson J.P., Andersson U.G. Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines. Immunopharmacology. 26:1993;11-20.
97. Natsumeda Y., Ohno S., Kawasaki H.et al. Two distinct cDNAs for human IMP dehydrogenase. J. Biol. Chem. 265:1990;5292-5295.
98. Nehme O.S., Overley C.A., O'Brien J.J. The role of mycophenolate mofetil in the management of refractory inflammatory bowel disease (IBD). Gastroenterology. 114(4 (Pt. 2)):1998;A1049.
99. Neurath M.F., Wanitschke R., Peters M.et al. Randomized trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gastroenterology. 114(4 (Pt. 2)):1998;A1050.
100. Neyts J., Andrei G., De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicro. Agents Chemother. 42:1998;216-222.
101. Neyts J., Andrei G., De Clercq E. The antiherpesvirus activity of H2G is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicro. Agents Chemother. 42:1998;3285-3289.
102. Neyts J., Meerbach A., McKenna P., De Chercq E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infection. Antiviral Res. 30:1996;125-132.
103. Noronha I.L., Fujihara C.K., Oliviera I.B., Leitao T.G., Zatz R. Enhanced interstitial expression of angiotensin II and TGF-β in the renal ablation model: effect of mycophenolate mofetil. J. Am. Soc. Nephrol. 9:1998;618A. (Abstr).
104. Nousari H.C., Griffin W.A., Anhalt G.J. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J. Am. Acad. Dermatol. 39:1998a;497-498.
105. Nousari H.C., Lynch W., Anhalt G.J., Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch. Dermatol. 134:1998;1509-1511.
106. Nowack R., Birch R., Van de Woude F.J. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet. 349:1997;774.
107. Nussenblatt R.B., Palestine A.G. Uveitis: Fundamentals and Clinical Practice. 1989;Year Book Medical Publishers, Chicago, USA.
108. O'Gara M.J., Lee C.H., Weinberg G.A., Nott J.M., Queener S.F. IMP dehydrogenase from Pneumocystis carinii as a potential drug target. Antimicro. Agents Chemother. 41:1997;40-48.
109. O'Hair D.P., McManus R.P., Komorowski R. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann. Thorac. Surg. 58:1994;1311-1315.
110. Ozchgfhj H.S., Hughes W.T. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to the provocative effects of tacrolimus, sirolimus and dexamethasone. J. Infect. Dis. 175:1997;901-904.
111. Pardo-Mindán F.J., Errasti P., Panizo A.et al. Decrease of apoptosis rate in patients treated with mycophenolate mofetil. Nephron. 82:1999;232-237.
112. Paul L.C., Muzaffar S., Valentin J.-F. Donor pretreatment with mycophenolate mofetil protects against ischemia-reperfusion injury. Transplantation. 65:1998;1193-1195.
113. Paul L.C., Myllärniemi M., Muzaffar S., Benediktsson H. Nitric oxide synthase inhibition is associated with decreased survival of cardiac allografts in the rat. Transplantation. 65:1996;1193-1195.
114. Penny M.J., Boyd R.A., Hall B.M. Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J. Am. Soc. Nephrol. 9:1998;2272-2282.
115. Peters G.J., Oosterhof A., Verkamp J.H. Effects of adenosine and deoxyadenosine on PHA stimulation of lymphocytes of man, horse and pig. Int. J. Biochem. 14:1982;377-385.
116. Pickenacker A., Luger T.A., Schwarz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch. Dermatol. 134:1998;378-379.
117. Platz K.P., Eckhoff D., Bechstein W.O.et al. RS-61443 for reversal of acute rejection in canine renal allografts. Surgery. 110:1991;736-741.
118. Platz K.P., Mueller A.R., Willimeki C.et al. Indications for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation. Transplant. Proc. 30:1998;1468-1469.
119. Platz K.P., Sollinger H.W., Hullett D.A.et al. RS-61443, a new, potent immuno-suppressive agent. Transplantation. 51:1990;27-31.
120. Räisänen-Sokolowski A., Vuoristo P.et al. Mycophenolate mofetil (MMF, RS-61443) inhibits proliferation of rat aortic allografts. Transplant. Immunol. 3:1995;342-351.
121. Reis A., Reinhard T., Sundmacher R.et al. Mycophenolate mofetil in ocular immunological disorders. A survey of the literature with 3 case reports. Klin. Monatsbl. Augenheilkd. 213:1998;257-261.
122. Richman D.D., Kornbluth R.S., Carson P.A. Failure of dideoxynucleosides to inhibit HIV replication in cultured human macrophages. J. Exp. Med. 166:1987;1144-1149.
123. Romero F., Rodriguez-Iturbe B., Parra G.et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int. 55:1999;945-955.
124. Rosenberg A.S., Singer A. Cellular basis of skin graft rejection: an in vivo model of immune-mediated tissue destruction. Annu. Rev. Immunol. 10:1992;333-358.
125. Schiff M.H., Leishman B. CellCept (mycophenolate mofetil-MMF), a new treatment for RA: a 12-week, double-blind, randomized, placebo-controlled withdrawal trial. Arthritis Rheum. 41(Suppl. 9):1998;S364.
126. Senda M., DeLustro B., Eugui E., Natsumeda Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation. 60:1995;1143-1148.
127. Shaffer D., Blakely M.L., Gottschalk R., Monaco A.P. Small bowel transplantation in rats using RS-61443: effect on GVHD and rejections. Transplant. Proc. 24:1992;1159-1160.
128. Shaffer D., Muanza T., Blakely M.L.et al. Prevention of graft-versus-host disease by RS-61443 in two different rodent models. Transplantation. 55:1993;221-223.
129. Shears L.L., Kawaharada N., Tzeng E.et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J. Clin. Invest. 100:1997;2035-2042.
130. Shoji Y. Effect of topical preparation of mycophenolic acid on experimental allergic contact dermatitis of guinea-pigs induced by dinitrofluorobenzene. J. Pharm. Pharmacol. 46:1994;643-646.
131. Sintchak M.D., Nimmesgern E. The structure of inosine monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology. 47:2000;163-184.
132. Steele D.M., Hullett D.A., Bechstein W.O.et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant. Proc. 25:1993;754-755.
133. Stojanovic T., Grave H.J., Gieseler R.K.et al. Enhanced renal allograft rejection by inhibitors of alloreactivity. Lab. Invest. 74:1996;496-512.
134. Stryer L. Biosynthesis of nucleotides. Biochemistry. 3rd edn. 1988;602-626 Freeman, New York.
135. Szabolcs M., Michler R.E., Yang X.et al. Apoptosis of cardiac myocytes during cardiac allograft rejection. Relation to inhibition of nitric oxide synthase. Circulation. 94:1996;1665-1673.
136. Szabolcs M.J., Ravalli S., Minanov O.et al. Apoptosis and increased expression of inducible nitric oxide synthase in human allograft rejection. Transplantation. 65:1998;804-812.
137. Thomson A.W., Woo J., Yao G.Z.et al. Effects of combined administration of FK-506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T-cell activation molecule expression in human mixed lymphocyte cultures. Transplant. Immunol. 1:1993;146-150.
138. Tutschka P.J., Beschorner W.E., Allison A.C.et al. Use of cyclosporin A in allogeneic bone marrow transplantation in the rat. Nature. 280:1979;148-150.
139. Van Bruggen M.C.J., Walgreen B., Riike T.P.M., Berden J.H.M. Attenuation of murine lupus nephritis by mycophenolate mofetil. J. Am. Soc. Nephrol. 9:1998;1407-1415.
140. Verham R., Meek T.D., Hedstrom L., Wang C.C. Purification, characterization and kinetic analysis of inosine-5′monophosphate dehydrogenase of Trichomonas foetus. Mol. Biochem. Parasitol. 24:1987;1-12.
141. Viklicky O., Hubácek J.A., Lácha J.et al. Long-term graft survival and ACE gene polymorphism. The Sixty Basic Sciences Symposium of the Transplantation Society, Monterey, CA. 1999;186.
142. Wang X., Lewis D.A., Kim H.K.et al. Alterations in mRNA for inducible endothelial nitric oxide synthase and plasma nitric oxide with rejection and/or infection of allotransplanted lungs. Transplantation. 66:1998;567-572.
143. Wang W., Tong M.K.H., Lee S.H., Chan L. Mycophenolate mofetil protects against renal ischemia-reperfusion injury by inhibiting osteopontin and ICAM-1 expression. Transplantation. 67:1999;537. (Abstr).
144. Wang C.C., Verham R., Cheng H.W.et al. Differential effects of inhibitors of purine metabolism on two trichomonad species. Biochem. Pharmacol. 33:1984;1323-1329.
145. Watarai Y., Takeuchi I., Togashi H., Yoshioka M.et al. Nitric oxide production in renal transplant recipients and iNOS expression in renal allografts. Transplantation. 67:1999;S9. (Abstr).
146. Waters R., Webster D., Allison A.C. Mycophenolic acid and some antioxidants induce differentiation of monocytic lineage cells and augment production of the IL-1 receptor antagonist. Ann. N. Y. Acad. Sci. 696:1993;185-196.
147. Wei W., Tong M.K.H., Chan L. Mycophenolic acid (MPA) inhibits the over-expression of osteopontin and ICAM-1 proteins in ischemia/reperfusion injury. J. Am. Soc. Nephrol. 9:1999;660A. (Abstr).
148. Weimer R., Melk A., Daniel V.et al. Monocyte responses in patients with chronic renal transplant rejection: beneficial effects of MMF-based immunosuppression. Transplantation. 67:1999;27. (Abstr).
149. Whitcup S.M., Nussenblatt R.B. Treatment of autoimmune uveitis. Am. NY Acad. Sci. 696:1993;307-318.
150. Winklhofer F., Dai F.-X., Cowley B.D. Jr.et al. Mycophenolate inhibits nitric oxide (NO) production via iNOS in renal allograft recipients. Transplantation. 67:1999;S218.
151. Wolberg G. Antipurines and purine metabolism. Handb. Exp. Pharmacol. 85:1988;517-550.
152. Wolff D., Kuerschner D., Skibbe T.et al. Treatment of high risk chronic GVHD with FK506, mycophenolate mofetil (MMF) and methylprednisolone (MP). Br. J. Haematol. 102:1998;210.
153. Worrall N.K., Misko P.P., Botney M.D.et al. Time course and cellular localization of indicible nitric oxide synthases expression during cardiac allograft rejection. Ann. Thorac. Surg. 67:1999;716-722.
154. Wu J.C. Mycophenolate mofetil: mechanisms of action. Perspect. Drug Discov. Design. 2:1994;185-204.
155. Yamaguchi Y., Olsabe K., Matsumura F.et al. Peroxynitrite formation during rat hepatic allograft rejection. Hepatology. 29:1999;777-784.
156. Yu C., Seidel K., Nash R.A., Deeg H.J., Sandmaier B.M., Barsoukov A. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical marrow grafts. Blood. 91:1998;2581-2587.
157. Zeeh J.M., Zorlu I., Riley N.E., Goebell H., Dignass A.U. Mycophenolate mofetil reduces tissue damage in an experimental model of colitis in rats. Gastroenterology. 114(4 (Pt. 2)):1998;A1122.
158. Zimmer-Molsberger B., Knauf W., Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anaemia. Lancet. 350:1997;1003-1004.
159. Zimmerman R.F., Miller G., Radhakrishnan J., Appel G.B. Mycophenolate mofetil (MMF) treatment of idiopathic membranous nephropathy (IMN). J. Am. Soc. Nephrol. 9:1998;103A.
160. Ziolo M.T., Bollinger S.S., Wabler G.M. Myocytes isolated from rejecting transplanted hearts exhibit reduced basal shortening which is reversible by aminoguanidine. J. Mol. Cell Cardiol. 30:1998;1009-1017.
161. Ziswiler R., Steinman-Niggli K., Kappeler A.et al. Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J. Am. Soc. Nephrol. 9:1998;2055-2066.